you, Thank Andrew.
ingredients. we've months, reports seen on speculating discussing of insecticide these on the of have profitability and our may few numerous portfolio, important growth active impact patent the published Over the long-term and expirations last diamide timing these the
on profitably that I but diamide key other expiration timing key want critical to of patents. clarity patent on to allow well grow to FMC will not patent estate take provide our the the elements to the further continue also franchise only today time and the milestones, beyond of
registration complexity. and recognition, other manufacturing as elements These supply commercial include protection, chain as strategies, and data critical well brand
It's Our two the names Cyazypyr ingredients current combined and diamide trademark chlorantraniliprole approximately annual important insect brand are Rynaxypyr portfolio with consists of revenues billion. and and note controls Cyazypyr FMC's key Rynaxypyr $X.X for that Cyantraniliprole. active molecules, to of
low trajectory. These quickly with two technology strong we established Rynaxypyr's fast-acting These and the combining it molecules growth to control. attributes long highly class-leading insect systemic performance, in control terms effective world's rates of residual continue leading dose a expect
to diamide begin the state. discussion of Slide XX our to patent Moving
IP building estate Let recognize went well me thought assets Out DuPont. first done. IP and extremely that XXXX, quality molecules these into was in the of protection the we pause of the acquired all to
largely which generally to several the and uses formulations, The true extended for with the active are though applications. the Today active of same intermediates - is different of composition Rynaxypyr, - certain confine months. patent up patent XX processes Cyazypyr estate intermediates timelines by I ingredients cover made comments comments will my manufacturing - - and certain ingredient families matter both both in Rynaxypyr
families filed observers Together we a total that granted are patent XX and pending molecule with XX% related granted have Cyazypyr XXX in XX pending the of patents most we patents patents. on. Composition to and X,XXX over countries, patent Rynaxypyr, have families focused For generally the and patents. cover of with matter of patents, and the close structure have
manufacturing the Cyazypyr, final active cover as and well important. key patents make both are to processes are products. Rynaxypyr intermediates and In patents the that the Process the for chlorantraniliprole these as process used extremely ingredients Cyantraniliprole, of case
a produce. complex molecule is Chlorantraniliprole to
them. important the these In commercial uses means which produce is no hence fact is are commercial there for that for production very This in other it of of intermediates steps, no XX sole chlorantraniliprole. outlets and production requires an many separate its other use intermediate as
Importantly, the FMC in expiration these all well of to has the next separately past of matter composition the intermediate process the cases of of of patented. these patents way and many process some stretch decade. run the end XX steps patents Several
profile patents. Rynaxypyr to intend is Cyazypyr has insect difficult be requirements manufacture by safety FMC's have regulatory making be stringent that Cyantraniliprole and safety process for rely made will these same meet it will required and such to the that regulatory FMC's generic and the to their FMC To protected the a which to molecule, AIs we're parties manufacture controls. Third way data on demonstrate sell chlorantraniliprole product products as
manufacturing alternative that currently these our ways We processes, manufacture to processes but Process not our note on do is patents that also patents are processes it impurity alternate alternate can profile. match are important hold diamide several used, diamides. but include to not
products specific used the use how they formulations, ingredient application patents cover are active in in of and applied. how the cover Formulation patents while are used an
of patent the protection In world patents estate, the means addition the further have can protection to have extend exclusive patent after afforded around after molecules patents the applicable period of of to a that use after composition holder holder bodies expired. added patented application regulatory expired. that various process in and form is This the timelines the offer of also registration the data
country patent slides, data account protection currently estate by the registration These for countries XX% how highlighted major show diamide I'll revenue. come of and coming Over our timeline the together. over
XX the Slide see entire how for we to timeline can Europe. Turning you view
We have two parts of protection.
composition have the we later in and countries. patent for of matter August protection First, certain through EU XXXX
In would and effect that patent have be required means EU we be for manufacture this will In December are that until addition importantly, patents. key Rynaxypyr. through our process XXXX December manufacture processes infringing protection in no or import chlorantraniliprole XXXX as they the to able to one
first a third-party protection, the use of granted Europe, cannot are the in ingredients who owners gain registration years means to for have XX of for exclusive data also registration. after data Second, effectively patented FMC active period which chlorantraniliprole a
will a speaking, further that this for initial during active FMC-generated apply to ingredient. of the end given runs through seeking re-registration period, use years addition, be data protection no the data means to of data register protection XXXX. which at chlorantraniliprole October can registration In Practically of the one, X.X the
from from framework products two the will that generate product protection XX license for data EU, data means This period it EU generally multi-layered in FMC. rules under could own of purposes competitive period QX of has specific but chlorantraniliprole expired, XXXX not after sales years. the their until for see party during takes unless take they sales should can start earliest the third apply at sourced under is this A registration then which registration, months, and or to we
different Slide you as patent protection not U.S. the see had process. to we can similar registration to same does data On what XX, a of a The with in the have EU but the chart regards EU. in with protection, type
product a the third data prior patent cannot U.S. However, in patent under or law, a expiration. test or to generate U.S. party sell
registration time cannot the This under which and party process take means patents any that that registration, a and normal third-party in to can chlorantraniliprole federal XXXX. manufacture to process XX main company apply December about circumstances allow regulatory gain the sell expiring months. wishing begin At third for will start company
to for been a each the granted. be granted, registration normally where sold. the be has an After months registration state federal state six needed These products state registrations is also take will additional
FMC's legally is FMC, case addition, holder, compensate a the In data registration. to this gain to the party data third required in for using
regulatory the This be are means until to timeline, by robust protection and we that unless third licensed earliest, not the supplied do expect US XXXX patent party able to sell they or in at chlorantraniliprole FMC. June
expire to China reviewed, India. Slide key key other see to expiring XXXX timeline for XXXX. composition other we've can matter and AI December that for countries which the shows countries begin two and XX, of patents Moving August Similar diamides: patents in the process you in the
has patent a start molecule a time the registration that third-party product China, protection. for India and In can during for frame a applying
the third in if chlorantraniliprole is have effectively the which not registration party means manufacturing at XXXX selling even start earliest. patented, QX granted, that processes competitive However, both we a until these key could the countries,
will county in Brazil on Finally, and begin I'll Slide expire key of The in ingredient longer our August most on the the other for process is in countries. patents XX. are patent last Rynaxypyr April patent will timelines The than Brazil XXXX. matter active XXXX composition cover expiring
can patents Under have regulatory apply practices, for the current expired. third-party Brazilian a registration before
has data law after initial use a initial of for of Brazil the protecting exclusive However, a of period the time, registration. registrant's
Brazilian law, competitive account, the regulatory this exclusivity filed occur to Taking respected. of with data authorities that our XXXX. exclusivity company any Brazilian legal not of registration first initiated that process FMC's we means have during foul falls the a this data will it have before period into for believes of FMC chlorantraniliprole continued sales September
XX. Slide to Turning
second of The for patent for the the we should approach. diamide is be clear commercial process diamides. coverage growth our very part air-tight of that the our It an have manufacturing strategy
and However, purchased or trademarks. the Rynaxypyr a license as insect from ingredient to of long sell others the they we and are controls Cyazypyr allowing active advancing formulations FMC also as strategy
ingredients EBITDA means expense it for our SG&A gross parties a market gross active the to increases the the margin for it third is Selling the dilutive. At margin absence drops reach profitable incremental us grow as not margin reasonable for a business EBITDA. way to molecule, is to of straight FMC
the The third-party into bears all selling customer. as ingredient a distributing well costs related to product formulated the to marketable active the product as and
actively expiration. Cyazypyr As in global or or supply Rynaxypyr new of place already are agreements today, more basis patent we with agreements a and have than commercial companies before on country XX negotiating to
additional already with we are to today. with opportunities explore We beyond XX companies continuing the engaged
the are of all majority third-party This means from beyond of well of the exclusive and The a our diamide FMC their their process patents. the the purchase large will in partners prior be over extends and of dates to expiration to agreements the patent duration requirements our expiration lifetime required agreement needs nature.
ongoing already prefer contracts The a is product many than to number manufacture that rather to negotiations demonstrates IP. we attempt would us where have signed supply all with companies complex protected that highly have competitors of by partner
Our to franchise. the market partners share. These geographies will diamide technologies today. FMC and leverage overall commercial These continue has the that with new access than different commercial growth crops will in be ensures formulations different strategy FMC different of additive to will the actives gain diamide
and the the diamide at have level. even the past level of an molecule of strong market expiration at share manufacturing the a patent growing business years stronger will date, with FMC a For grower share the
long-term the diamides protection manufacturing of of strategy, enjoys in economies strength FMC complexity of scale aspects and further significant of patent our platform. under-appreciated the Beyond are commercial the
as all active manufacturing and via XX-step very for to party third in requirements. long-term and exclusive manufactures replicate final the undertaking agreement with FMC supply would our a all partners intermediates ingredient Rynaxypyr required large process chain capital complex plants be manufacturing the under products well network the this as Today, major a own
In scale are will in addition, of partnership substantially with formulated in the any choose diamide given that do explains market the participate know-how to so the This companies to why FMC. new we lower than manufacturing have confident, cost be our operations, we FMC's will most entrant. want in
In the FMC's of addressed franchise. about closing, growth any diamide of misperceptions hope long-term I sustainable
ensure supply as patent that to beyond. deep partners. manufacturing knowledge, driver strong Our company as diamides further party for proprietary the to third major diamides of well FMC recognition to a This will and estate will continues choice of data, and regulatory next FMC end scale approach is of commercial brand franchise decade through the the that value be ensure a
with call Pierre. And turn back I'll to that, the
